Article
Oncology
Reiko Mitsueda, Hiroko Toda, Yoshiaki Shinden, Kosuke Fukuda, Ryutaro Yasudome, Mayuko Kato, Naoko Kikkawa, Takao Ohtsuka, Akihiro Nakajo, Naohiko Seki
Summary: Accumulating evidence indicates that the miR-30 family plays a critical role in various human cancers, acting as either tumor suppressors or oncogenes. The downregulation of miR-30c-1-3p and miR-30c-2-3p in cancer tissues is associated with worse prognosis in breast cancer (BrCa) patients, and overexpression of these miRNAs inhibits cancer cell aggressiveness, suggesting their tumor-suppressor function in BrCa cells. Furthermore, TRIP13 is identified as a direct target of these two miRNAs and its inactivation attenuates BrCa cell aggressiveness and prevents malignant transformation. Understanding the molecular networks controlled by miRNAs, including passenger strands, may lead to the identification of diagnostic markers and therapeutic targets for BrCa.
Article
Oncology
Roisin M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard L. Piekarz, Karen L. Smith, Ursa A. Brown-Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, George T. Budd, Ellis G. Levine, Melanie E. Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano
Summary: The combination of entinostat and exemestane did not improve survival in patients with AI-resistant advanced HR-positive, HER2-negative breast cancer. E2112 phase III trial: no benefit seen in adding HDAC inhibitor entinostat to exemestane in advanced breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Chemistry, Medicinal
Jie Wang, Zhuoxian Cao, Fang Wang, Pan Wang, Jianxiong An, Xiaozhong Fu, Ting Liu, Yan Li, Yongjun Li, Yonglong Zhao, Hening Lin, Bin He
Summary: The study discusses the rational design, synthesis, biological evaluation, molecular docking, and in vivo efficacy study of a class of HDAC inhibitors using N-acetyl lysine mimics derived from cysteine. These inhibitors demonstrated potent HDAC inhibition and broad cytotoxicity against several cancer cell lines, and compound 13d showed significant tumor growth inhibition in a A549 xenograft mice model.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Guoshun Luo, Xin Lin, Shengnan Ren, Shuangjie Wu, Xin Wang, Luyu Ma, Hua Xiang
Summary: A series of dual SERDs/HDAC inhibitors were designed and synthesized, some of which showed significant HDAC6 inhibition and improved antiproliferative activity, with the most potent compound also exhibiting strong ERα binding affinity and antiproliferative activity.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Xu Han, Minghui Li, Jin Xu, Jingyue Fu, Xinyang Wang, Jingyi Wang, Tiansong Xia, Shui Wang, Ge Ma
Summary: This study found that the expression level of miR-1275 is decreased in chemoresistant breast cancer, and low levels of miR-1275 are associated with poor overall survival. Knocking out miR-1275 increases chemoresistance in breast cancer cells by increasing cancer stem cell properties. miR-1275 could serve as a prognostic biomarker and therapeutic target for breast cancer patients.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Oncology
Feng Chi, Jiayi Liu, Samuel W. Brady, Patrick A. Cosgrove, Aritro Nath, Jasmine A. McQuerry, Sumana Majumdar, Philip J. Moos, Jeffrey T. Chang, Michael Kahn, Andrea H. Bild
Summary: In the treatment of breast cancer, chemotherapy can induce cancer stem cell-like (CSL) traits in tumor cells, including resistance to chemotherapy and decreased differentiation. The use of a pan-HDAC inhibitor, belinostat, can block the chemotherapy-induced CSL phenotype and reduce the progenitor cell characteristics in cancer cells.
TRANSLATIONAL ONCOLOGY
(2021)
Review
Cell Biology
Boya Peng, Poh Ying Theng, Minh T. N. Le
Summary: miR-125b, a key miRNA in cancer pathogenesis, is deregulated in various types of cancer and plays important roles in tumourigenesis and cancer progression. Its potential as a diagnostic and prognostic biomarker, as well as a therapeutic tool against cancer, is supported by emerging evidence on its essential functions.
CELL PROLIFERATION
(2021)
Article
Biochemistry & Molecular Biology
Alisha N. Jones, Andreas Walbrun, Fabio Falleroni, Matthias Rief, Michael Sattler
Summary: MicroRNAs (miRNAs) are small noncoding RNAs that play a role in post-transcriptional downregulation of specific target genes. This study investigates the structural effects of a cancer-linked G/A mutation in the terminal loop of pri-miR-30c RNA and its influence on binding by SRSF3 and hnRNP A1 RBPs involved in its processing. The results reveal that both wildtype and G/A variant pri-miR-30c RNAs adopt similar structures and bind SRSF3. However, the G to A mutation partially destabilizes the dimer in the variant transcript, promoting recognition and binding by hnRNP A1. These findings provide insights into the conformational effects of a G/A mutation in pri-miR-30c RNA and its potential impact on cancer.
JOURNAL OF MOLECULAR BIOLOGY
(2022)
Review
Medicine, General & Internal
Silvia Grassilli, Valeria Bertagnolo, Federica Brugnoli
Summary: miR-29b has a controversial role in breast cancer, acting both as a tumor suppressor and as an onco-miRNA. The different isoforms of miR-29b have a dual effect on breast tumor features, depending on the prevailing function, mature miR-29b expression, and breast tumor characteristics. miR-29b-3p and miR-29b1-5p play distinct roles in breast tumors with different phenotypes.
Article
Oncology
Yueyang Liu, Weiwei Gong, Konstantina Panoutsopoulou, Thirza Singer-Cornelius, Katharina Augustin, Holger Bronger, Marion Kiechle, Julia Dorn, Andreas Scorilas, Margaritis Avgeris, Viktor Magdolen, Tobias Dreyer
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with poor patient outcome. In this study, the potential prognostic impact of miR-27a, miR-206, and miR-214 in TNBC was evaluated. Elevated expression of these micro-RNAs was significantly associated with shortened disease-free survival and increased chemoresistance. These findings suggest that miR-27a, miR-206, and miR-214 may serve as novel molecular targets for TNBC therapy.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Oncology
Wenjie Xia, Wuzhen Chen, Chao Ni, Xuli Meng, Jun Wu, Qiong Yang, Hongchao Tang, Hongjun Yuan, Shan Fang
Summary: In this study, PTX-induced exosomal circBACH1 was found to promote stemness and migration of BC cells by sponging miR-217 to upregulate the expression of G3BP2. This provides a new therapeutic target for PTX-resistance and progression of BC via the circBACH1/miR-217/G3BP2 axis.
BREAST CANCER RESEARCH
(2023)
Article
Oncology
Jun Ni, Xun Xi, Sujian Xiao, Xigang Xiao
Summary: The study revealed that circHIPK3 was up-regulated in PTX-resistant BC tissues and cells, and silencing circHIPK3 enhanced PTX sensitivity in vitro and in vivo. Additionally, circHIPK3 modulated PTX resistance in BC cells by regulating the miR-1286/HK2 axis.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Zheng Li, Yaming Li, Xiaolong Wang, Yiran Liang, Dan Luo, Dianwen Han, Chen Li, Tong Chen, Hanwen Zhang, Ying Liu, Zekun Wang, Bing Chen, Lijuan Wang, Wenjing Zhao, Qifeng Yang
Summary: Long non-coding RNA LINC01977 is identified as a key oncogenic driver in breast cancer, promoting cancer progression and chemoresistance to doxorubicin by functioning as a ceRNA to prevent GOLM1 gene from miRNA-mediated repression. This discovery suggests LINC01977 could serve as a novel prognostic indicator and help develop more effective therapeutic approaches for breast cancer patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ferda Ari, Rudolf Napieralski, Oguzhan Akgun, Viktor Magdolen, Engin Ulukaya
Summary: The study compared the effects of standard chemotherapy regimens and epigenetic modulators on gene methylation levels, expression status, and differentiation of tumour biomarkers in breast cancer cell models. The results suggest potential therapeutic benefits in reducing tumour malignancy.
CELL BIOCHEMISTRY AND FUNCTION
(2021)
Review
Oncology
Junxin Li, Jing Shen, Yueshui Zhao, Fukuan Du, Mingxing Li, Xu Wu, Yu Chen, Shurong Wang, Zhangang Xiao, Zhigui Wu
Summary: miR-181a-5p is an important miRNA that can post-transcriptionally suppress targeted genes and is associated with various diseases. It plays a regulatory role in different types of cancer, potentially serving as a diagnostic and prognostic biomarker and influencing chemoresistance.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2023)